Contributing to a Sustainable and Green Economy
Climate change and environmental degradation pose urgent global threats and the biopharmaceutical industry has a role to play by both understanding and improving the interface between people, health and the environment.1 Pfizer recognizes the profound societal and public health impacts that are expected to result from environmental issues.
Improve and Accelerate Equitable Access to Innovative Therapies
Since the 1990s, the pharmaceutical industry has brought over 1,100 new medicines to patients in Europe.1 However, major variations in health outcomes remain evident across Europe. For instance, people born today in Sweden can expect to live in good health about 20 years longer than people in Latvia.2 Among the contributing factors to this discrepancy is the wide variation in access to innovative medicines.
Ensuring flexible and resilient supply chains
The debate around supply chains for medicines has drastically accelerated with the Covid-19 pandemic. The European Commission’s recent initiative to establish a Structured dialogue on security of medicines supply is an important move. Patients, governments, industry and other supply chain actors all have insights, experiences to contribute.
Investment in a robust research and development (R&D) infrastructure
The pharmaceutical industry is the most R&D intensive industrial sector in Europe. R&D lies at the core of our innovative industry, bringing with it hope for patients and the prospect of long-term health system sustainability while contributing to Europe’s economic growth.
The European Innovation Ecosystem
The European pharmaceutical industry is a driving force for the European economy delivering a world-class environment for clinical research and pharmaceutical production. It is positioned as the second-largest pharmaceutical market globally, accounting for 22% of all pharmaceutical sales.